Theravance Biopharma Inc
Statements
Cash Flow
Theravance Biopharma Inc (TBPH) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -8.9 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 16 | Q4 16 | Q1 17 | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12 | -28 | -50 | -45 | -62 | -44 | 50 | -62 | -49 | -52 | -81 | -48 | -45 | -64 | -55 | -53 | -77 | -65 | -70 | -50 | -45 | -42 | -26 | -15 | -22 | -124 | -11 | -12 | -2.5 | -0.9 | -1.0 | -4.4 | -5.2 | -0.9 | 43 | 208 | -6.5 | -6.1 | 73 | -8.9 | 52 | |
| 0.8 | 1.2 | 1.1 | 1.0 | 1.0 | 1.0 | 0.9 | 0.8 | 0.6 | 0.9 | 1.7 | 1.5 | 1.9 | 1.1 | 2.3 | 2.6 | 2.0 | 1.1 | 2.3 | 2.4 | 2.6 | 2.4 | 1.3 | 1.9 | 1.8 | 2.0 | 1.0 | 0.9 | 0.9 | 1.4 | 1.2 | 1.0 | 0.8 | 0.7 | 1.1 | 0.9 | 0.6 | 1.5 | 0.8 | 1.4 | 4.4 | |
| 9.9 | 10 | 10 | 10 | 11 | 18 | 14 | 14 | 12 | 12 | 12 | 11 | 13 | 24 | 15 | 17 | 16 | 16 | 16 | 15 | 14 | 17 | 15 | 9.7 | 8.5 | 7.0 | 7.0 | 6.3 | 6.3 | 5.8 | 5.2 | 5.4 | 5.0 | 5.8 | 4.9 | 4.5 | 4.6 | 4.5 | 4.5 | 6.0 | 20 | |
| 9.9 | 10 | 10 | 11 | 18 | 18 | 13 | 15 | 12 | 5.7 | 12 | 11 | 13 | 24 | 31 | 17 | 16 | 15 | 16 | 15 | 15 | -5.3 | 14 | 7.1 | 6.0 | -172 | 7.1 | 7.6 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 11 | 28 | 3.9 | 9.5 | -15 | 24 | 101 | -32 | -0.7 | -8.4 | -16 | -13 | -4.6 | 1.5 | -7.4 | -1.2 | -17 | -14 | -13 | -13 | -7.7 | -7.5 | -4.0 | 2.0 | -15 | 60 | 2.3 | -5.9 | -1.3 | -3.4 | 4.1 | 2.7 | -0.3 | 14 | 52 | 158 | -17 | 262 | 76 | -78 | 243 | |
| 0.4 | 0.4 | 0.6 | 0.7 | 0.8 | 0.3 | 2.8 | 1.1 | 1.9 | 1.5 | 1.2 | 0.6 | 0.1 | 1.3 | 1.0 | 2.4 | 2.1 | 1.2 | 1.8 | 0.2 | 1.0 | 0.4 | 0.3 | 0.1 | 0.1 | 0.3 | 0.9 | 0.9 | 0.0 | 0.7 | 0.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -50 | -46 | -124 | 11 | 15 | 41 | -11 | 42 | 47 | 99 | -72 | -1.3 | -24 | 14 | 68 | -177 | 67 | 52 | 114 | 36 | -36 | 11 | 32 | 7.5 | 1,075 | 39 | -43 | 11 | 0.0 | -0.7 | 17 | -3.0 | -17 | 16 | 31 | -36 | -100 | 0.6 | 53 | -60 | -107 | |
| 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | – | – | – | – | – | 380 | – | – | 387 | – | – | – | 119 | – | – | – | 0.8 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -0.6 | -1.0 | -4.0 | -2.1 | -1.2 | -1.2 | -1.7 | -5.2 | -1.5 | -1.4 | -1.7 | -0.5 | -0.6 | -0.4 | -6.8 | -1.1 | -1.0 | -0.8 | -5.6 | -0.7 | -2.3 | -0.5 | -1.4 | -0.3 | -95 | -36 | -56 | -81 | -31 | -31 | -1.7 | -0.5 | -0.4 | -0.5 | -0.9 | -0.5 | -0.7 | -2.0 | -5.8 | 5.8 | -2.7 | |
| – | 222 | – | – | – | – | 229 | 229 | 229 | 229 | -2.2 | -2.2 | -2.2 | -2.2 | 128 | -0.3 | 11 | -5.7 | -5.7 | -5.0 | – | – | – | – | -632 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| 0.5 | 332 | -1.2 | 3.0 | -0.8 | 0.6 | -1.7 | -2.4 | -0.3 | 230 | -1.4 | 4.4 | -0.1 | -1.5 | 261 | 1.9 | -1.0 | 0.7 | -11 | 105 | -2.3 | 0.1 | -1.4 | 0.1 | -722 | -35 | -56 | -81 | -31 | -31 | -1.7 | 0.0 | -0.4 | -0.4 | -0.9 | -0.5 | -0.4 | -1.5 | -5.6 | 4.6 | -2.9 | |
| -62 | 258 | -175 | -30 | -48 | -2.3 | 37 | -22 | -2.7 | 277 | -155 | -45 | -68 | -52 | 275 | -228 | -11 | -12 | 33 | 91 | -84 | -31 | 4.4 | -7.1 | 331 | -120 | -111 | -82 | -34 | -32 | 14 | -7.5 | -23 | 14 | 73 | 171 | -107 | -7.0 | 120 | -65 | -59 | |
| -13 | -29 | -51 | -45 | -63 | -44 | 47 | -63 | -51 | -54 | -82 | -49 | -45 | -66 | -56 | -56 | -79 | -66 | -72 | -50 | -46 | -43 | -26 | -15 | -22 | -124 | -12 | -13 | -2.5 | -1.5 | -1.1 | -4.5 | -5.2 | -1.1 | 43 | 208 | -6.5 | -6.1 | 73 | -8.9 | 52 |
LTM = last twelve months (sum of the four most recent quarters).
Showing the most recent 40 periods — older statements are on file for this stock.
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.